Michael Vincent Meluzio Sells 5,628 Shares of Cue Biopharma (NASDAQ:CUE) Stock

Cue Biopharma, Inc. (NASDAQ:CUE) VP Michael Vincent Meluzio sold 5,628 shares of Cue Biopharma stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $30.09, for a total value of $169,346.52. Following the transaction, the vice president directly owned 48,961 shares in the company, valued at approximately $1,473,236.49. The trade was a 10.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cue Biopharma Price Performance

Shares of NASDAQ:CUE traded down $6.56 during mid-day trading on Monday, reaching $27.64. 305,202 shares of the company traded hands, compared to its average volume of 363,425. The company’s 50 day moving average price is $29.50 and its 200-day moving average price is $146.00. The firm has a market cap of $116.09 million, a PE ratio of -1.02 and a beta of 2.47. Cue Biopharma, Inc. has a 52 week low of $4.97 and a 52 week high of $45.50.

Cue Biopharma (NASDAQ:CUE) last released its earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). Cue Biopharma had a negative return on equity of 482.58% and a negative net margin of 435.83%.The firm had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3.00 million.

Analysts Set New Price Targets

A number of research analysts recently weighed in on CUE shares. Wall Street Zen downgraded shares of Cue Biopharma from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Cue Biopharma in a research report on Thursday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Institutional Investors Weigh In On Cue Biopharma

Institutional investors have recently added to or reduced their stakes in the stock. GC Wealth Management RIA LLC raised its position in shares of Cue Biopharma by 35.0% during the fourth quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock valued at $1,415,000 after buying an additional 1,200,000 shares during the last quarter. Boothbay Fund Management LLC boosted its position in shares of Cue Biopharma by 15.3% during the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after acquiring an additional 93,333 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc boosted its position in shares of Cue Biopharma by 1,231.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after acquiring an additional 407,568 shares during the last quarter. Stifel Financial Corp grew its stake in Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Cue Biopharma in the 3rd quarter valued at $62,000. 35.04% of the stock is owned by hedge funds and other institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.